GENO Stock Overview
Genovis AB (publ.) designs, develops, and sells tools for development of new treatment methods and diagnostics for customers in the pharmaceutical and medical device industries.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 6/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Genovis AB (publ.) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr31.00 |
52 Week High | kr67.00 |
52 Week Low | kr29.50 |
Beta | 1.47 |
1 Month Change | -34.94% |
3 Month Change | -40.50% |
1 Year Change | -45.61% |
3 Year Change | -17.55% |
5 Year Change | 152.03% |
Change since IPO | -71.03% |
Recent News & Updates
Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings
Feb 22Recent updates
Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings
Feb 22These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts
Feb 20Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be
Feb 04Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors
Oct 06Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?
Jun 22What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?
May 13Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?
Dec 22Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?
Nov 14If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity
Jul 08Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?
Jun 01Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%
May 10One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically
Feb 10Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?
Aug 09What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?
Mar 27How Does Genovis AB (publ.)'s (STO:GENO) CEO Pay Compare With Company Performance?
Dec 30Is Now An Opportune Moment To Examine Genovis AB (publ.) (STO:GENO)?
Nov 23Shareholder Returns
GENO | SE Life Sciences | SE Market | |
---|---|---|---|
7D | -21.7% | -5.2% | 0.8% |
1Y | -45.6% | 6.7% | 15.0% |
Return vs Industry: GENO underperformed the Swedish Life Sciences industry which returned 8.1% over the past year.
Return vs Market: GENO underperformed the Swedish Market which returned 16.1% over the past year.
Price Volatility
GENO volatility | |
---|---|
GENO Average Weekly Movement | 7.7% |
Life Sciences Industry Average Movement | 6.9% |
Market Average Movement | 6.1% |
10% most volatile stocks in SE Market | 12.6% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: GENO's share price has been volatile over the past 3 months.
Volatility Over Time: GENO's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 37 | Fredrik Olsson | https://www.genovis.com |
Genovis AB (publ.) designs, develops, and sells tools for development of new treatment methods and diagnostics for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; GingisKHAN, a cysteine protease that digests human IgG1; and FabDELLO, a protease that digests human IgG1.
Genovis AB (publ.) Fundamentals Summary
GENO fundamental statistics | |
---|---|
Market cap | kr2.03b |
Earnings (TTM) | kr61.50m |
Revenue (TTM) | kr158.23m |
33.0x
P/E Ratio12.8x
P/S RatioIs GENO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GENO income statement (TTM) | |
---|---|
Revenue | kr158.23m |
Cost of Revenue | kr15.16m |
Gross Profit | kr143.07m |
Other Expenses | kr81.57m |
Earnings | kr61.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 24, 2024
Earnings per share (EPS) | 0.94 |
Gross Margin | 90.42% |
Net Profit Margin | 38.87% |
Debt/Equity Ratio | 0% |
How did GENO perform over the long term?
See historical performance and comparison